Hantavirus Global Situational Briefing — June 26, 2026

The June 26 picture is quieter operationally than it was a week ago, but not empty. The M/V Hondius-linked Andes virus event is now largely a monitoring-tail and after-action story: CDC says all U.S. monitoring is complete and no Americans developed hantavirus disease, while ECDC's public count remains 13 cases and 3 deaths. The more active surveillance signal is Argentina's domestic hantavirosis season, where the latest national event table places 2026 notifications above the 2022-2025 median.

The strongest new official statement this week is from CDC. In its June 24 response update, CDC said the 42-day monitoring period for all potentially exposed U.S. citizens had ended, that all monitoring activities in the United States were complete, and that none of the Americans involved became ill. CDC also said the illness and deaths occurred among residents of other countries. 1

That should change how the ship event is weighted. It is no longer behaving like an expanding multi-country outbreak. ECDC's page still carries the 17 June public tally of 13 total cases, including 12 confirmed and one probable case, with three deaths, and it states that additional event-related cases are considered very unlikely on current information. 2 WHO's earlier Disease Outbreak News report had already placed global risk at low while keeping a moderate risk category for exposed passengers and crew during the incubation window. 7

The tail is still useful. CDC said its disease ecologists traveled to Argentina to work with local public health and epidemiology partners on trapping and testing rodents in outbreak-connected areas. Preliminary testing of trapped rodents was negative, and CDC described the likely source of exposure as still under investigation. 1 That keeps the source-investigation question open even as contact monitoring winds down.

Australia's endpoint is consistent with the same trajectory. On 19 June, Health Minister Mark Butler said the six passengers held in Western Australia, five Australians and one New Zealander, had remained well, tested negative, and were expected to leave quarantine at the end of the 42-day period on 23 June. He also said all 13 global cases then reported were connected with M/V Hondius and that WHO had not reported an additional case since the one in Spain almost four weeks earlier. 5

Canada remains a useful check on the North American side of the response. PHAC's current professional page still reports one laboratory-confirmed Canadian case among M/V Hondius passengers and describes the general-population risk in Canada as low. 6 Its contact-management guidance keeps a conservative 42-day minimum quarantine and active daily monitoring framework for high-risk contacts, including passengers and crew on the ship after 1 April who were not consistently protected by appropriate PPE. 8

Argentina's newest national bulletin item is not a full hantavirosis chapter. It is a summary table in BEN 813, covering epidemiological week 23, and it gives the calendar-year signal: 50 accumulated hantavirosis events in 2026 versus a 2022-2025 median of 29. The bulletin classifies hantavirosis as above expected in the year-to-date comparison and above expected in the latest four-week window. 3

The better severity baseline is still BEN 812. It reported 108 confirmed seasonal cases through week 22 of the 2025-2026 season, concentrated in Buenos Aires, Salta, Santa Fe, Jujuy, Rio Negro, Entre Rios, and Chubut. The season's national incidence was 0.23 per 100,000. 4 That same report recorded 36 deaths, a 33.3% case-fatality proportion, and a national mortality rate of 0.76 deaths per 1,000,000 inhabitants through week 22. 4

Two details from BEN 812 still matter for surveillance. First, the current season sat above the national outbreak threshold for most of the analyzed period, while the Centre and South regions exceeded outbreak thresholds and the Northwest remained in the alert zone. 4 Second, the Ministry described field investigations outside historically endemic areas: a Rio Colorado, Rio Negro case prompted environmental work in Rio Negro and La Pampa, and a three-case household cluster in Cerro Centinela, Chubut showed Andes virus sequences with 99.99% similarity among the human cases. The bulletin judged the pattern compatible with human-to-human transmission, while noting that zoonotic exposure could not be excluded because a peridomestic rodent was hantavirus-positive and its viral sequencing was still pending. 4

The practical reading: Argentina is not just providing context for the cruise-ship source investigation. It has a domestic season with elevated burden, high lethality, and localized exposure investigations that can affect how clinicians and surveillance teams classify febrile respiratory illness in rural or peri-rural settings.

WHO's latest EPI-WIN IPC webinar page is careful about transmission. It says limited human-to-human Andes virus transmission is known to occur, that the exact contribution of different routes in the M/V Hondius outbreak remains under study, and that WHO is operating under assumptions that can include contact with an infected person or contaminated surfaces, direct deposition of infectious respiratory particles onto mucosal surfaces, and airborne transmission. The same page also says the virus does not show the transmission dynamics of highly transmissible airborne pathogens such as measles. 9

That is why the current policy discussion is about proportionate isolation, safe discharge, and quarantine operations, not about broad community restrictions. The same WHO event identifies open operational questions around when to discontinue transmission-based precautions, how to approach discharge decisions, and how to run quarantine in home or facility settings. 9

The research response is now formalized. WHO announced the NAVIS natural-history study on 12 June: a 21-country initiative designed to study Andes virus transmission dynamics, incubation periods, immune responses, viral kinetics, and determinants of severe disease using harmonized longitudinal follow-up of exposed individuals. 10 For an event that appears to be winding down epidemiologically, that study may be the main source of future high-value updates.

On countermeasures, the bottom line remains conservative. A June npj Viruses review states that there are no licensed vaccines or approved therapeutics for Andes hantavirus, and that current standard care is supportive management such as oxygenation, fluid balancing, mechanical ventilation, and, where needed, renal or advanced cardiopulmonary support. 11 A separate Gavi summary of the recent mRNA vaccine work reports complete protection in a lethal Syrian hamster model after one dose, with antibodies detectable by 14 days, but it also stresses that the result is preclinical and that human trials are the next step. 12

The next useful public signal is likely to come from one of three places. First, Argentina's next national bulletin can clarify whether the week-23 above-expected hantavirosis signal continues and whether any new case-level investigation is disclosed. Second, WHO, ECDC, PHAC, CDC, or national authorities may publish after-action material on quarantine thresholds, discharge criteria, or contact-management evidence. Third, NAVIS or related research groups may start releasing early natural-history or virology findings from the exposed cohorts.

Until one of those changes, the working assessment is stable: the ship-linked Andes virus cluster remains at 13 cases and 3 deaths in the latest ECDC public count, U.S. and Australian exposed-traveler monitoring endpoints have closed without new public disease cases, and Argentina's domestic hantavirosis season remains the highest-priority surveillance thread for day-to-day monitoring.